Pazopanib, Pemetrexed and Crizotinib for Advanced Disease
Pazopanib, Pemetrexed and Crizotinib for Advanced Disease
A Two Steps Phase I Trial of Pazopanib or Pemetrexed in Combination With Crizotinib Followed by the Triplet, Crizotinib Plus Pazopanib Plus Pemetrexed in Patients With Advanced Malignancies (2011-1142)
Summary
Using a combination of drugs may be more effective than using one drug alone for treating advanced breast cancer. Crizotinib (Xalkori) blocks a protein called ALK, which is involved in cancer cell growth and survival. It is approved to treat some types of non-small cell lung cancer. Pazopanib (Votrient) blocks the growth of blood vessels that supply nutrients needed for tumor growth. It is approved for the treatment of advanced kidney cancer. Pemetrexed (Alimta) blocks proteins that may cause tumors to grow. It is approved for the treatment of non-small cell lung cancer. The goal of this trial is to identify the highest tolerable dose and to study the safety of the combination of crizotinib and pazopanib; crizotinib and pemetrexed; and crizotinib, pazopanib and pemetrexed in patients with advanced breast cancer. Patients with other types of advanced cancer are also being enrolled in this study.
This is a Phase I trial
|